Minocycline HCl microspheres reduce red-complex bacteria in periodontal disease therapy.
BACKGROUND
The objective of this trial was to measure the antimicrobial effects of a minocycline HCl microsphere (MM) local drug-delivery system when used as an adjunct to scaling and root planing (SRP). DNA probe analysis for 40 bacteria was used to evaluate the oral bacteria of 127 subjects with moderate to advanced chronic periodontitis.


METHODS
Subjects were randomly assigned to either SRP alone (N = 65) or MM + SRP (N = 62). The primary endpoints of this study were changes in numbers and proportions of the red-complex bacteria (RCB) and the sum of Porphyromonas gingivalis, Tannerella forsythia (formally T. forsythensis), and Treponema denticola relative to 40 oral bacteria at each test site from baseline to day 30. Numbers of RCB from the five test sites were averaged to provide a value for each subject.


RESULTS
MM + SRP reduced the proportion of RCB by 6.49% and the numbers by 9.4 x 10(5). The reduction in RCB proportions and numbers by SRP alone (5.03% and 5.1 x 10(5), respectively) was significantly less. In addition, MM + SRP reduced probing depth by 1.38 mm (compared to 1.01 mm by SRP alone), bleeding on probing was reduced by 25.2% (compared to 13.8% by SRP alone), and a clinical attachment level gain of 1.16 mm (compared to 0.80 mm by SRP alone) was achieved.


CONCLUSIONS
These observations support the hypothesis that RCBs are responsible for periodontal disease and that local antimicrobial therapy using MM + SRP effectively reduces numbers of RCBs and their proportions to a greater extent than SRP alone.
Department of Clinical Research, The Forsyth Institute, Boston, MA 02115, USA. mgoodson@forsyth.org
J Max
JM
Goodson
John C
JC
Gunsolley
Sara G
SG
Grossi
Paul S
PS
Bland
Joan
J
Otomo-Corgel
Frances
F
Doherty
Judy
J
Comiskey
D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001419:Bacteria / Q000145:classification / Q000187:drug effects*; D001439:Bacteroides / Q000187:drug effects / Q000302:isolation & purification; D015169:Colony Count, Microbial; D003773:Dental Plaque / Q000382:microbiology; D012534:Dental Scaling; D016503:Drug Delivery Systems; D005260:Female; D005884:Gingival Hemorrhage / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage / Q000627:therapeutic use*; D017622:Periodontal Attachment Loss / Q000188:drug therapy / Q000382:microbiology; D010514:Periodontal Pocket / Q000188:drug therapy / Q000382:microbiology; D010518:Periodontitis / Q000188:drug therapy / Q000382:microbiology*; D016966:Porphyromonas gingivalis / Q000187:drug effects / Q000302:isolation & purification; D016745:Root Planing; D016037:Single-Blind Method; D016896:Treatment Outcome; D048373:Treponema denticola / Q000187:drug effects / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D008911:Minocycline